PepGen Inc. is a biotech company focused on developing oligonucleotide therapeutics to aid in the treatment of severe neuromuscular & neurologic illnesses, with a lead product candidate PGN-EDO51 in Phase I clinical trials. Besides, the company is also researching PGN-EDODM1 as a potential treatment for myotonic dystrophy type 1. The company was set up in 2018 and has its base in Cambridge, Massachusetts.